Studies on the predictive factors of treatment outcome after intravitreal injection of Lucentis (ranibizumab) in eyes with macular edema associated with central retinal vein occlusion (CRVO)

Trial Profile

Studies on the predictive factors of treatment outcome after intravitreal injection of Lucentis (ranibizumab) in eyes with macular edema associated with central retinal vein occlusion (CRVO)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Central retinal vein occlusion; Retinal oedema
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 May 2014 New source identified and integrated (ClinicalTrials.gov record: NCT02091505).
    • 17 Mar 2014 According to the ClinicalTrials.gov record, planned end date changed to 1 May 2016.
    • 17 Jan 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top